Management of chronic cluster headache

Massimo Leone, Angelo Franzini, Alberto Proietti Cecchini, Eliana Mea, Giovanni Broggi, Gennaro Bussone

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Opinion statement: Primary cluster headache (CH) is an excruciatingly severe pain condition. Several pharmacologic agents are available to treat chronic CH, but few double-blind, randomized clinical trials have been conducted on these agents in recent years, and the quality of the evidence supporting their use is often low, particularly for preventive agents. We recommend sumatriptan or oxygen to abort ongoing headaches; the evidence available to support their use is good (Class I). Ergotamine also appears to be an effective abortive agent, on the basis of experience rather than trials. We consider verapamil and lithium to be first-line preventives for chronic CH, although the trial evidence is at best Class II. Steroids are clearly the most effective and quick-acting preventive agents for chronic CH, but long-term steroid use carries a risk of several severe adverse effects. We therefore recommend steroids only if verapamil, lithium, and other preventive agents are ineffective. In rare cases, patients experience multiple daily cluster headaches for years and are also refractory to all medications. These patients almost always develop severe adverse effects from chronic steroid use. Such patients should be considered for neurostimulation. Occipital nerve stimulation is the newest and least invasive neurostimulation technique and should be tried first; the evidence supporting its use is encouraging. Hypothalamic stimulation is more invasive and can be performed only in specialist neurosurgical centers. Published experience suggests that about 60% of patients with chronic CH obtain long-term benefit with hypothalamic stimulation.

Original languageEnglish
Pages (from-to)56-70
Number of pages15
JournalCurrent Treatment Options in Neurology
Volume13
Issue number1
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Cluster Headache
Steroids
Verapamil
Lithium
Ergotamine
Sumatriptan
Headache
Randomized Controlled Trials
Oxygen
Pain

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Management of chronic cluster headache. / Leone, Massimo; Franzini, Angelo; Proietti Cecchini, Alberto; Mea, Eliana; Broggi, Giovanni; Bussone, Gennaro.

In: Current Treatment Options in Neurology, Vol. 13, No. 1, 02.2011, p. 56-70.

Research output: Contribution to journalArticle

Leone, M, Franzini, A, Proietti Cecchini, A, Mea, E, Broggi, G & Bussone, G 2011, 'Management of chronic cluster headache', Current Treatment Options in Neurology, vol. 13, no. 1, pp. 56-70. https://doi.org/10.1007/s11940-010-0106-5
Leone, Massimo ; Franzini, Angelo ; Proietti Cecchini, Alberto ; Mea, Eliana ; Broggi, Giovanni ; Bussone, Gennaro. / Management of chronic cluster headache. In: Current Treatment Options in Neurology. 2011 ; Vol. 13, No. 1. pp. 56-70.
@article{35d25c488e2e4b87b495a28bbb33c867,
title = "Management of chronic cluster headache",
abstract = "Opinion statement: Primary cluster headache (CH) is an excruciatingly severe pain condition. Several pharmacologic agents are available to treat chronic CH, but few double-blind, randomized clinical trials have been conducted on these agents in recent years, and the quality of the evidence supporting their use is often low, particularly for preventive agents. We recommend sumatriptan or oxygen to abort ongoing headaches; the evidence available to support their use is good (Class I). Ergotamine also appears to be an effective abortive agent, on the basis of experience rather than trials. We consider verapamil and lithium to be first-line preventives for chronic CH, although the trial evidence is at best Class II. Steroids are clearly the most effective and quick-acting preventive agents for chronic CH, but long-term steroid use carries a risk of several severe adverse effects. We therefore recommend steroids only if verapamil, lithium, and other preventive agents are ineffective. In rare cases, patients experience multiple daily cluster headaches for years and are also refractory to all medications. These patients almost always develop severe adverse effects from chronic steroid use. Such patients should be considered for neurostimulation. Occipital nerve stimulation is the newest and least invasive neurostimulation technique and should be tried first; the evidence supporting its use is encouraging. Hypothalamic stimulation is more invasive and can be performed only in specialist neurosurgical centers. Published experience suggests that about 60{\%} of patients with chronic CH obtain long-term benefit with hypothalamic stimulation.",
author = "Massimo Leone and Angelo Franzini and {Proietti Cecchini}, Alberto and Eliana Mea and Giovanni Broggi and Gennaro Bussone",
year = "2011",
month = "2",
doi = "10.1007/s11940-010-0106-5",
language = "English",
volume = "13",
pages = "56--70",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Management of chronic cluster headache

AU - Leone, Massimo

AU - Franzini, Angelo

AU - Proietti Cecchini, Alberto

AU - Mea, Eliana

AU - Broggi, Giovanni

AU - Bussone, Gennaro

PY - 2011/2

Y1 - 2011/2

N2 - Opinion statement: Primary cluster headache (CH) is an excruciatingly severe pain condition. Several pharmacologic agents are available to treat chronic CH, but few double-blind, randomized clinical trials have been conducted on these agents in recent years, and the quality of the evidence supporting their use is often low, particularly for preventive agents. We recommend sumatriptan or oxygen to abort ongoing headaches; the evidence available to support their use is good (Class I). Ergotamine also appears to be an effective abortive agent, on the basis of experience rather than trials. We consider verapamil and lithium to be first-line preventives for chronic CH, although the trial evidence is at best Class II. Steroids are clearly the most effective and quick-acting preventive agents for chronic CH, but long-term steroid use carries a risk of several severe adverse effects. We therefore recommend steroids only if verapamil, lithium, and other preventive agents are ineffective. In rare cases, patients experience multiple daily cluster headaches for years and are also refractory to all medications. These patients almost always develop severe adverse effects from chronic steroid use. Such patients should be considered for neurostimulation. Occipital nerve stimulation is the newest and least invasive neurostimulation technique and should be tried first; the evidence supporting its use is encouraging. Hypothalamic stimulation is more invasive and can be performed only in specialist neurosurgical centers. Published experience suggests that about 60% of patients with chronic CH obtain long-term benefit with hypothalamic stimulation.

AB - Opinion statement: Primary cluster headache (CH) is an excruciatingly severe pain condition. Several pharmacologic agents are available to treat chronic CH, but few double-blind, randomized clinical trials have been conducted on these agents in recent years, and the quality of the evidence supporting their use is often low, particularly for preventive agents. We recommend sumatriptan or oxygen to abort ongoing headaches; the evidence available to support their use is good (Class I). Ergotamine also appears to be an effective abortive agent, on the basis of experience rather than trials. We consider verapamil and lithium to be first-line preventives for chronic CH, although the trial evidence is at best Class II. Steroids are clearly the most effective and quick-acting preventive agents for chronic CH, but long-term steroid use carries a risk of several severe adverse effects. We therefore recommend steroids only if verapamil, lithium, and other preventive agents are ineffective. In rare cases, patients experience multiple daily cluster headaches for years and are also refractory to all medications. These patients almost always develop severe adverse effects from chronic steroid use. Such patients should be considered for neurostimulation. Occipital nerve stimulation is the newest and least invasive neurostimulation technique and should be tried first; the evidence supporting its use is encouraging. Hypothalamic stimulation is more invasive and can be performed only in specialist neurosurgical centers. Published experience suggests that about 60% of patients with chronic CH obtain long-term benefit with hypothalamic stimulation.

UR - http://www.scopus.com/inward/record.url?scp=79551528806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551528806&partnerID=8YFLogxK

U2 - 10.1007/s11940-010-0106-5

DO - 10.1007/s11940-010-0106-5

M3 - Article

C2 - 21107766

AN - SCOPUS:79551528806

VL - 13

SP - 56

EP - 70

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 1

ER -